Spots Global Cancer Trial Database for Study of XL999 in Patients With Multiple Myeloma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of XL999 in Patients With Multiple Myeloma
Official Title: A Phase 2 Study of XL999 in Subjects With Relapsed/Refractory Multiple Myeloma
Study ID: NCT00304590
Conditions
Interventions
Study Description
Brief Summary: This clinical study is being conducted at multiple sites to determine the activity, safety, and tolerability of XL999 when given weekly to patients with relapsed or refractory multiple myeloma. XL999 is a small molecule inhibitor of cellular factors including VEGFR, PDGFR, and FGFR that may be involved in multiple myeloma.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
UCLA Oncology-Hematology Associates, Ltd., Los Angeles, California, United States
University of Chicago, Chicago, Illinois, United States
Joliet Oncology-Hematology Associates, Ltd., Joliet, Illinois, United States
Contact Details
Name: Lynne Bui, MD
Affiliation: Exelixis
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
